Wanbury Ltd
Incorporated in 1988, Wanbury Ltd is in the business of pharmaceutical and related activities, including research[1]
- Market Cap ₹ 852 Cr.
- Current Price ₹ 260
- High / Low ₹ 291 / 87.9
- Stock P/E 31.6
- Book Value ₹ 6.70
- Dividend Yield 0.00 %
- ROCE 62.5 %
- ROE %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 27.4% CAGR over last 5 years
Cons
- Stock is trading at 38.8 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 7.34% over past five years.
- Promoters have pledged 76.7% of their holding.
- Earnings include an other income of Rs.28.9 Cr.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
459 | 661 | 250 | 420 | 432 | 370 | 391 | 367 | 392 | 511 | 485 | 557 | 560 | |
491 | 637 | 228 | 387 | 414 | 438 | 375 | 344 | 374 | 475 | 459 | 484 | 493 | |
Operating Profit | -32 | 25 | 21 | 33 | 19 | -68 | 16 | 23 | 18 | 36 | 26 | 73 | 68 |
OPM % | -7% | 4% | 9% | 8% | 4% | -18% | 4% | 6% | 5% | 7% | 5% | 13% | 12% |
5 | -78 | 6 | 0 | 90 | 76 | 9 | 84 | 2 | 77 | -3 | 26 | 29 | |
Interest | 37 | 48 | 19 | 32 | 36 | 31 | 40 | 33 | 23 | 21 | 21 | 29 | 31 |
Depreciation | 23 | 23 | 5 | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 12 | 13 | 13 |
Profit before tax | -87 | -125 | 4 | -7 | 62 | -32 | -25 | 65 | -12 | 81 | -10 | 56 | 52 |
Tax % | 0% | 2% | 28% | 0% | 1% | -1% | -1% | 0% | 2% | -0% | 1% | 1% | |
-87 | -128 | 3 | -7 | 62 | -32 | -25 | 64 | -13 | 81 | -10 | 56 | 52 | |
EPS in Rs | -50.19 | -63.95 | 1.60 | -3.58 | 26.71 | -13.49 | -10.48 | 25.79 | -5.04 | 24.94 | -3.18 | 17.09 | 15.98 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 7% |
3 Years: | 12% |
TTM: | 6% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 27% |
3 Years: | 68% |
TTM: | 1165% |
Stock Price CAGR | |
---|---|
10 Years: | 19% |
5 Years: | 81% |
3 Years: | 47% |
1 Year: | 196% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 17 | 20 | 20 | 20 | 23 | 24 | 24 | 25 | 25 | 33 | 33 | 33 |
Reserves | -65 | -212 | -214 | -209 | -176 | -208 | -233 | -168 | -181 | -56 | -66 | -11 |
415 | 389 | 381 | 362 | 300 | 250 | 260 | 190 | 192 | 100 | 95 | 116 | |
406 | 209 | 209 | 215 | 265 | 207 | 236 | 232 | 253 | 276 | 241 | 205 | |
Total Liabilities | 773 | 406 | 396 | 388 | 412 | 273 | 286 | 279 | 289 | 353 | 304 | 343 |
423 | 174 | 164 | 180 | 186 | 178 | 172 | 164 | 167 | 167 | 167 | 167 | |
CWIP | 25 | 13 | 19 | 14 | 10 | 10 | 9 | 14 | 11 | 2 | 2 | 3 |
Investments | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
324 | 219 | 213 | 193 | 216 | 84 | 105 | 101 | 111 | 183 | 135 | 174 | |
Total Assets | 773 | 406 | 396 | 388 | 412 | 273 | 286 | 279 | 289 | 353 | 304 | 343 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
87 | 68 | 40 | 43 | 43 | 32 | 30 | 44 | 17 | 41 | 20 | 4 | |
-21 | -6 | -5 | -20 | -13 | -1 | -3 | 64 | 8 | 1 | -9 | -17 | |
-64 | -71 | -30 | -28 | -27 | -33 | -27 | -108 | -17 | -29 | -32 | 15 | |
Net Cash Flow | 3 | -9 | 5 | -5 | 3 | -2 | -0 | -0 | 7 | 13 | -21 | 2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 67 | 57 | 144 | 65 | 71 | 29 | 41 | 50 | 32 | 45 | 52 | 59 |
Inventory Days | 63 | 42 | 103 | 69 | 63 | 27 | 36 | 25 | 41 | 60 | 26 | 43 |
Days Payable | 114 | 113 | 301 | 172 | 260 | 174 | 209 | 253 | 221 | 218 | 179 | 196 |
Cash Conversion Cycle | 15 | -14 | -55 | -38 | -125 | -118 | -131 | -177 | -148 | -113 | -101 | -94 |
Working Capital Days | -159 | -3 | -26 | -45 | -132 | -195 | -175 | -212 | -168 | -103 | -102 | -20 |
ROCE % | -11% | 4% | 12% | 57% | -1% | 26% | 31% | 27% | 46% | 21% | 62% |
Documents
Announcements
-
Board Meeting Intimation for Notice Of Board Meeting For Approving The Un-Audited Financial Results Of The Company For The Second Quarter And Six Months Ended 30Th September, 2024.
5 Nov - Notice of Board Meeting for Q2 financial results.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
22 Oct - Intimation of duplicate share certificates issued.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Oct - Certificate pursuant to Reg 74(5) of SEBI (DP) Reg, 2018 for the quarter ended 30th Sept., 2024
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
7 Oct - Issuance of duplicate share certificates for shareholder.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 28 Sep
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Business Overview:[1]
WL is a pharmaceutical company with a presence in the API global market and domestic branded Formulation. It’s majorly into Active Pharmaceutical Ingredient (API) Sales & Marketing in over 50 countries and Pan-India
Formulation presence